Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1384&sort=-start_date
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-start_date", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1405&sort=-start_date", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1385&sort=-start_date", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1383&sort=-start_date" }, "data": [ { "type": "Grant", "id": "7057", "attributes": { "award_id": "3U42OD011123-16S1", "title": "WaNPRC Macaca nemestrina SPF Breeding Colony", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 6567, "first_name": "MATTHEW ERIN", "last_name": "Arnegard", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2002-09-30", "end_date": "2024-05-31", "award_amount": 571856, "principal_investigator": { "id": 22854, "first_name": "CHARLOTTE", "last_name": "HOTCHKISS", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 159, "ror": "https://ror.org/00cvxb145", "name": "University of Washington", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 22855, "first_name": "Sally", "last_name": "Thompson-Iritani", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 159, "ror": "https://ror.org/00cvxb145", "name": "University of Washington", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "Summary: The goal of this project is to maintain and enhance the specific pathogen free (SPF) pigtail macaque (M. nemestrina) breeding colony at the Washington National Primate Research Center (WaNPRC). This colony is the only major domestic breeding colony of M. nemestrina and the primary source of this important animal model for AIDS studies and other types of biomedical research in the United States. M. nemestrina have unique immunological, genetic, behavioral, anatomical, and physiological characteristics that make them an essential model in a number of areas of research related to HIV/AIDS. Specific pathogens (SIV, SRV, STLV-1, McHV-1) are a threat to animal or human health, or interfere with research and must be excluded to optimize nonhuman primate research models. In this proposal we discuss how we will maintain the WaNPRC SPF M. nemestrina breeding colony to provide animals of the highest quality to meet research needs. The SPF colony is housed at two locations, the Arizona Breeding Colony (ABC) which is an integral part of the WaNPRC, and at the New Iberia Research Center (NIRC). Having animals at two sites raises some challenges, but provides for contingencies in case of adverse events, and we have established lines of communication to ensure consistency. At both sites we will use innovative bioinformatics tools to increase cost effectiveness by maximizing production per animal. In addition, in our Seattle Infant Primate Research Laboratory (IPRL) we will initiate breeding for the production of expanded SPF M. nemestrina, which will be free of simian foamy virus (SFV), cytomegalovirus (MnCMV), rhadinovirus (MnRV), and simian varicella (SVV). Viral exclusion testing for all present and future excluded viruses will be performed by the Primate Diagnostic Services Laboratory (PDSL) through the virology core. We will use state-of-the-art genomics to characterize the animals, focusing on expressed alleles in the MHC region through the MHC Genetic Typing Core.", "keywords": [ "AIDS/HIV problem", "Acquired Immunodeficiency Syndrome", "Adverse event", "Alleles", "Anatomy", "Animal Genetics", "Animal Model", "Animals", "Area", "Arizona", "Behavioral", "Biomedical Research", "Breeding", "Characteristics", "Chickenpox", "Communication", "Communities", "Complex", "Cytomegalovirus", "Diagnostic Services", "Ensure", "Epithelial", "Epithelium", "Exclusion", "Exhibits", "Exposure to", "Faculty", "Future", "Genetic", "Genomics", "Goals", "Grant", "Guidelines", "Health", "Human", "Immune response", "Immunologics", "Infant", "Infection", "Infrastructure", "Laboratories", "Laboratory Research", "Location", "Macaca", "Macaca mulatta", "Macaca nemestrina", "Maintenance", "Mission", "Modeling", "Pathogenicity", "Physiological", "Primates", "Production", "Productivity", "Research", "Research Personnel", "Resources", "Rhadinovirus", "Risk", "SIV", "Sales", "Simian Foamy Virus", "Simian T-lymphotropic virus 1", "Site", "Source", "Subfamily lentivirinae", "Testing", "United States", "United States National Institutes of Health", "Vagina", "Viral", "Virus", "Washington", "animal breeding", "animal care", "base", "bioinformatics tool", "cost", "cost effectiveness", "germ free condition", "human disease", "human model", "improved", "innovation", "keratinization", "microbicide", "microorganism", "nonhuman primate", "pathogen", "pre-exposure prophylaxis", "vaginal microbiome", "virology" ], "approved": true } }, { "type": "Grant", "id": "7266", "attributes": { "award_id": "3U01DK062413-19S1", "title": "Genetic and genomic approaches to better understand the clinical heterogeneity in inflammatory bowel diseases", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)" ], "program_reference_codes": [], "program_officials": [ { "id": 12352, "first_name": "Terez", "last_name": "Shea-Donohue", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2002-09-30", "end_date": "2022-07-31", "award_amount": 346893, "principal_investigator": { "id": 12399, "first_name": "Dermot Patrick", "last_name": "McGovern", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 766, "ror": "https://ror.org/02pammg90", "name": "Cedars-Sinai Medical Center", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 766, "ror": "https://ror.org/02pammg90", "name": "Cedars-Sinai Medical Center", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "The inflammatory bowel diseases (IBD), Crohn's disease (CD) and ulcerative colitis (UC), are significant causes of morbidity with recent estimates suggesting there are more than 3 million Americans with IBD with very significant financial burden to the US economy. The world is currently in the middle of a global pandemic caused by SARS-CoV2 which is the cause of COVID- 19. Preliminary studies have identified shared molecular signatures between IBD and COVID-19. Of interest is that the receptor for SARS-COV2 is angiotensin converting enzyme 2 (ACE2) which is most highly expressed in the gut. Our preliminary data suggests that expression of this receptor is influenced by age and obesity as well as in IBD. Differing patterns suggest differences by disease location. Interestingly our preliminary data suggest that anti-cytokine therapy alters ACE2 expression in inflamed tissue. We propose to study the overlap between these 2 conditions using a large-scale and comprehensive genetic approach. We will study genetic variants in ACE2 and related genes for their effect on IBD susceptibility and disease progression as well as response to therapy. We will study, in depth, large numbers of gene expression samples from IBD cases to investigate this overlap further. We will use a newer technology called single cell RNAseq to determine which cells are leading to the changes in gene expression that we have seen with our initial studies. We will also use a statistical approach called Mendelian Randomization (which can be viewed as nature’s equivalent of a randomized study) to determine whether the therapies used in IBD are likely to be beneficial or harmful in COVID-19 infection. We will use these data to identify subjects in whom to generate pluripotent stem cells for functional work. For the functional studies we will use gut organoids and the IPSCs to test the effect of cytokines that reflect the different inflammatory states that we have observed (ageing, obesity, ileal inflammation, colonic inflammation) on ACE2 expression. The results from these analyses will also help us refine our ‘big data’ approach described earlier. We anticipate that these studies will give us insights into the molecular overlap of IBD and COVID-19 and what are the likely effects of anti-cytokine and other treatments used in IBD likely to be in COVID-19.", "keywords": [ "2019-nCoV", "Adult", "Affect", "Age", "Aging", "Air", "American", "Anti-Cytokine Therapy", "Area", "Back", "Big Data", "Biology", "Body mass index", "COVID-19", "Cells", "Colon", "Crohn&apos", "s disease", "Data", "Data Set", "Disease", "Disease Progression", "Disease susceptibility", "Enterocytes", "Epithelial", "Epithelial Cells", "Epithelium", "Financial Hardship", "Gene Expression", "Genes", "Genetic", "Genetic study", "Genomic approach", "Genomics", "Glycoproteins", "Human", "Immune", "In Vitro", "Individual", "Infection", "Inflammation", "Inflammatory", "Inflammatory Bowel Diseases", "Institutional Review Boards", "Interleukin-12", "Intestines", "Investigation", "Large Intestine", "Libraries", "Life", "Liquid substance", "Location", "Luciferases", "Mediating", "Messenger RNA", "Metabolic Diseases", "Methods", "Molecular", "Molecular Profiling", "Morbidity - disease rate", "National Institute of Diabetes and Digestive and Kidney Diseases", "Natural History", "Nature", "Obesity", "Operative Surgical Procedures", "Organoids", "Outcome", "Pathway interactions", "Patients", "Pattern", "Peptidyl-Dipeptidase A", "Pharmaceutical Preparations", "Pharmacotherapy", "Pluripotent Stem Cells", "Postoperative Period", "Property", "Proteins", "Publishing", "Quality of life", "Randomized", "Recombinants", "Relative Risks", "Reporting", "Research", "Resistance", "Resources", "Risk", "Role", "Safety", "Sampling", "Schedule", "Severities", "Site", "Small Intestines", "Societies", "Specimen", "System", "TNF gene", "Testing", "Tissues", "Ulcerative Colitis", "Variant", "Viral", "Viral Proteins", "Virus", "Work", "X Chromosome", "base", "behavioral response", "cell injury", "clinical effect", "clinical heterogeneity", "cohort", "comorbidity", "cytokine", "disorder subtype", "experimental study", "genetic approach", "genetic association", "genetic signature", "genetic variant", "genome wide association study", "genome-wide", "ileum", "in vivo", "induced pluripotent stem cell", "inflammatory disease of the intestine", "insight", "interest", "intestinal epithelium", "luminescence", "male", "member", "mortality", "mouse model", "new technology", "next generation sequencing", "novel", "pandemic disease", "polygenic risk score", "receptor", "receptor expression", "response", "single-cell RNA sequencing", "statistics", "transcriptomics" ], "approved": true } }, { "type": "Grant", "id": "7334", "attributes": { "award_id": "3R37DA015612-17S1", "title": "Making Better Decisions: Policy Modeling for AIDS and Drug Abuse", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Drug Abuse (NIDA)" ], "program_reference_codes": [], "program_officials": [ { "id": 21884, "first_name": "PETER", "last_name": "HARTSOCK", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2002-09-25", "end_date": "2023-11-30", "award_amount": 380547, "principal_investigator": { "id": 23122, "first_name": "DOUGLAS K", "last_name": "OWENS", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 266, "ror": "https://ror.org/00f54p054", "name": "Stanford University", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 266, "ror": "https://ror.org/00f54p054", "name": "Stanford University", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "In 2019, our competitive renewal for our NIDA-funded work on opioids, HIV, and HCV was funded with a MERIT award. In this supplement to our MERIT grant, we will address pressing issues in vulnerable populations at risk from SARS-CoV-2. We will adapt the modeling frameworks we have developed to address how best to protect vulnerable populations from COVID-19, including people who inject drugs (PWID), people who are incarcerated, and people in other vulnerable settings, including long-term care facilities, and schools. We will address strategies to protect vulnerable populations, including physical distancing measures, scaled-up and targeted testing and tracing, and strategic deployment of new technological innovations in diagnostics, therapeutics and vaccines as they arise. Our aims are to: 1. Model the intersecting epidemics of SARS-CoV-2, HIV and HCV in opioid-using and related vulnerable populations. We will extend our foundational epidemic models of HIV and HCV to include SARS- CoV-2. Doing so enables us to analyze the impacts of strategies in Aims 2 and 3. 2. Model the epidemiologic and population health impacts of currently available strategies to prevent and mitigate the harms from transmission of SARS-CoV-2 in vulnerable populations. We will evaluate prevention strategies involving physical distancing and intensive testing programs for vulnerable populations. We will assess the impact of strategies on epidemiologic outcomes including incidence, prevalence, mortality, life expectancy, quality of life, and quality-adjusted life years (QALYs). 3. Model the epidemiologic and population health impacts of future strategies, including improved therapeutics and vaccines, to prevent and mitigate the harms from transmission of SARS-CoV-2 in populations of interest. Because no single and sustainable strategy based on currently available technologies will likely have sufficient impact on reducing risks of continuing SARS-CoV-2 transmission, we will examine selected key strategies based on technologies that may become available in the next 18 months, particularly the use of a partially effective vaccine. The proposed work will synergistically expand on our current project and provide clinicians and policymakers with critically needed guidance about which strategies can most efficiently mitigate the national public health crisis from COVID-19 in vulnerable populations and settings.", "keywords": [ "2019-nCoV", "Acquired Immunodeficiency Syndrome", "Address", "Alcohol or Other Drugs use", "Award", "Businesses", "COVID-19", "Clinical Trials", "Communities", "Data", "Diagnostic", "Diagnostic tests", "Disease Outbreaks", "Drug abuse", "Effectiveness", "Epidemic", "Epidemiology", "Foundations", "Funding", "Future", "Government", "Grant", "Guidelines", "HIV", "HIV/HCV", "Health", "Health care facility", "Hepatitis C Therapy", "Imprisonment", "Incidence", "Individual", "Injecting drug user", "Institution", "International", "Life Expectancy", "Long-Term Care", "Male Circumcision", "Measures", "Modeling", "Monitor", "National Institute of Drug Abuse", "Neutralization Tests", "Opioid", "Outcome", "Peer Review", "Policies", "Population", "Populations at Risk", "Prevalence", "Prevention", "Prevention strategy", "Public Health", "Publishing", "Quality of life", "Quality-Adjusted Life Years", "Research", "Resources", "Risk", "Schools", "Shelter facility", "Technology", "Testing", "Therapeutic", "Uncertainty", "Vaccines", "Vulnerable Populations", "Work", "authority", "base", "epidemiologic data", "epidemiological model", "experience", "improved", "infection risk", "interest", "mortality", "opioid policy", "opioid use", "pandemic disease", "population health", "pre-exposure prophylaxis", "prevent", "programs", "response", "scale up", "screening", "technological innovation", "transmission process", "vaccination strategy" ], "approved": true } }, { "type": "Grant", "id": "5839", "attributes": { "award_id": "3R01AI052116-19S1", "title": "Spatiotemporal Control of T cell Synapse Stabilization and Signaling", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 20029, "first_name": "Chao", "last_name": "Jiang", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2002-09-15", "end_date": "2021-12-31", "award_amount": 161649, "principal_investigator": { "id": 20030, "first_name": "MATTHEW F", "last_name": "KRUMMEL", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 768, "ror": "https://ror.org/043mz5j54", "name": "University of California, San Francisco", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "T cells utilize surface-bound T cell receptors (TCR) at the immunological synapse with antigen-presenting cells (APC). Detection of their peptide-MHC ligands results in rapid intracellular signaling, necessary for acquisition of effector functions and for profound adaptive immunity. While we now understand some of the fundamental proteins in this processing, understanding how each works together in the context of a rapidly moving T cell has proven difficult. TCR recognition happens as surface deformations provide initial contact. However, despite various fixed and lower-resolution approaches to understanding this process, it has not been previously possible to study this complete surface in real-time in the full 3-dimensions in which it takes place. Here, we will use novel and advanced imaging approaches to define how cytoskeletally-driven membrane movements provide a backbone for efficient ligand detection and we will describe how a range of widely variant environmental cues as well as novel pathways alter this process and affect immune surveillance. This project will define how T cells effectively `find' their ligands amidst a sea of competing MHC. This efficiency of search and detection has clear implications for the ability of T cells to discovery rare epitopes and initiate a response, for example during the early phases of a viral infection.", "keywords": [ "3-Dimensional", "Actins", "Address", "Affect", "Affinity", "Agonist", "Antibodies", "Antigen-Presenting Cells", "Antigens", "Behavior", "Belief", "CRISPR screen", "Cell Surface Receptors", "Cell membrane", "Cell surface", "Cells", "Cues", "Data", "Detection", "Environment", "Epitopes", "Equilibrium", "Extracellular Matrix", "Genes", "Glycocalyx", "Goals", "Image", "Immune", "Immune response", "Immunity", "Immunologic Surveillance", "In Situ", "In Vitro", "Individual", "Ligands", "Link", "Membrane", "Membrane Biology", "Membrane Proteins", "Methods", "Movement", "Mutation", "National Institute of Allergy and Infectious Disease", "Organ", "Pathway interactions", "Peptide/MHC Complex", "Phase", "Process", "Proteins", "Research Personnel", "Resolution", "Scanning", "Sea", "Signal Transduction", "Specificity", "Speed", "Structure", "Surface", "Surveys", "Synapses", "System", "T-Cell Receptor", "T-Lymphocyte", "Technology", "Testing", "Time", "Tissues", "Variant", "Vertebral column", "Virus Diseases", "Width", "Work", "ZAP-70 Gene", "adaptive immunity", "antigen detection", "behavior in vitro", "cell cortex", "cell motility", "cell type", "cellular microvillus", "chemokine", "density", "imaging approach", "immune function", "immunological synapse", "in vivo", "interstitial", "lymph nodes", "migration", "novel", "receptor", "response", "spatiotemporal", "synaptogenesis", "transcription factor", "tumor microenvironment" ], "approved": true } }, { "type": "Grant", "id": "7180", "attributes": { "award_id": "3P30CA093373-18S3", "title": "Cancer Center Support Grant P30", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [ { "id": 20549, "first_name": "Sonya", "last_name": "Roberson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2002-07-01", "end_date": "2021-06-30", "award_amount": 167310, "principal_investigator": { "id": 22973, "first_name": "PRIMO N.", "last_name": "LARA", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 746, "ror": "", "name": "UNIVERSITY OF CALIFORNIA AT DAVIS", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 746, "ror": "", "name": "UNIVERSITY OF CALIFORNIA AT DAVIS", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "The purpose of this 12-month study, “Impact of COVID-19 on cancer-related behaviors among nonmetropolitan and minorities in inland northern California: Seeking mitigation strategies” is to measure the impact of COVID-19 on cancer-related behaviors among 1,000 adult respondents and to explore whether telemedicine could be a mitigating factor. These respondents will intentionally over-represent non-metropolitan residents, African Americans, Native Americans, and populations who have Limited English Proficiency. Briefly, the aims are to [1] finalize IRB-approved instruments to measure the impact of COVID-19 on non-metropolitan and minority residents; [2] conduct data collection from these vulnerable populations in the UCDCCC catchment area; [3] disseminate findings to affected populations and to the NCI and professional audiences with the intent to apply insights to mitigation strategies. This Study will utilize qualitative data collection methods, e.g., mail, phone, FaceTime or its Android counterparts, and in-person to characterize responses from non-metropolitan residents, Native Americans, and populations who have limited English proficiency and qualitative research methods (key informant interviews and focus groups) to compile and develop responses from African Americans so that a patient-centered, telemedicine approach could be enhanced. These different methods reflect the premise that “one size does not fit all” and will facilitate the outreach strategies and opportunities in place. Successful achievements of these Aims will result in data that are not only aggregated for the full sample but also dis-aggregated by group (e.g., Native Americans) so that potential solutions might also be customized and shared with collaborators which include Feather River Tribal Health, Northern Valley Indian Health, bilingual/bicultural workers, and UC Davis Comprehensive Cancer Center.", "keywords": [ "Achievement", "Adult", "Affect", "African American", "Android", "Asian Americans", "Behavior", "COVID-19", "California", "Cancer Center", "Cancer Center Support Grant", "Cancer Grant Supplements (P30)", "Canis familiaris", "Caring", "Catchment Area", "Characteristics", "Chinese People", "Clinical Trials", "Collaborations", "Communities", "Comprehensive Cancer Center", "Custom", "Data", "Data Collection", "Diagnostic Neoplasm Staging", "Doctor of Medicine", "Doctor of Philosophy", "Early Diagnosis", "English Language", "Family", "Feathers", "Focus Groups", "Funding", "Health", "Health Services Accessibility", "Health Status", "Hepatitis B Vaccination", "Household", "Human Papillomavirus", "Image", "Individual", "Institutional Review Boards", "Interview", "Koreans", "Latino", "Lead", "Limited English Proficiency", "Malignant Neoplasms", "Master of Public Health", "Measures", "Methods", "Midwestern United States", "Minority", "Moon", "NCI Center for Cancer Research", "Native Americans", "Neighborhood Health Center", "Patient Care", "Patients", "Persons", "Pharmaceutical Preparations", "Population", "Prenatal care", "Prevention", "Provider", "Qualitative Research", "Reporting", "Research", "Research Methodology", "Respondent", "Risk", "Risk Reduction", "Rivers", "Role", "Rural", "Sampling", "Screening for cancer", "Telemedicine", "Telephone", "Testing", "Translating", "Vaccination", "Visit", "Voice", "Vulnerable Populations", "Xenograft procedure", "bilingualism", "cancer health disparity", "cancer prevention", "cancer therapy", "experience", "improved", "informant", "innovation", "insight", "instrument", "medical specialties", "nonmetropolitan area", "outreach", "pandemic disease", "patient oriented", "response", "routine care", "socioeconomics", "tribal health" ], "approved": true } }, { "type": "Grant", "id": "4973", "attributes": { "award_id": "3P20GM103446-22S1", "title": "Genomic Surveillance of SARS-CoV-2 in the State of Delaware", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)" ], "program_reference_codes": [], "program_officials": [ { "id": 17877, "first_name": "KRISHAN", "last_name": "ARORA", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2001-09-30", "end_date": "2024-04-30", "award_amount": 515000, "principal_investigator": { "id": 17878, "first_name": "MELINDA K", "last_name": "DUNCAN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 442, "ror": "https://ror.org/01sbq1a82", "name": "University of Delaware", "address": "", "city": "", "state": "DE", "zip": "", "country": "United States", "approved": true }, "abstract": "The virus responsible for causing the COVID-19 pandemic, SARS-CoV-2, has a diverse genomic landscape that is quickly evolving. It has been challenging for the medical and scientific community to keep up with numerous variants and their association with clinical outcomes. The impact of the pandemic in the United States has been devasting for the healthcare industry and economic infrastructure. Enhanced genomic surveillance efforts are needed to be better understand how transmission patterns and virus evolution affects clinical outcomes. This project proposal focuses on increasing SARS-CoV-2 genome sequencing in pediatric patients and disseminating the demographic analysis for all samples sequenced in the State of Delaware Public Health Laboratory (>10,000). This project is leveraging key expertise in a collaborative effort between the top pediatric hospital in Delaware, Nemours, and the State of Delaware Public Health Laboratory.", "keywords": [ "2019-nCoV", "Abnormal coordination", "Acute", "Adult", "Affect", "Age", "Bioinformatics", "Biological", "Biological Assay", "COVID-19", "COVID-19 pandemic", "COVID-19 patient", "COVID-19 surveillance", "Case Fatality Rates", "Case Study", "Cessation of life", "Child", "Childhood", "Clinical", "Clinical Data", "Code", "Communities", "Complex", "Coupled", "Data", "Delaware", "Demographic Analyses", "Deposition", "Diagnosis", "Disease Outcome", "Disease Progression", "Ecosystem", "Ethnic Origin", "Evolution", "Fostering", "Genes", "Genomics", "Geographic Locations", "Gold", "Grant", "Health", "Health Personnel", "Health system", "Healthcare Industry", "Healthcare Systems", "Hospitals", "Individual", "Infrastructure", "Institution", "Laboratories", "Link", "Medical", "Mutation", "Outcome", "Patients", "Pattern", "Pediatric Hospitals", "Population", "Public Health", "RNA Viruses", "Race", "Reporting", "Research Technics", "SARS coronavirus", "SARS-CoV-2 genome", "SARS-CoV-2 infection", "SARS-CoV-2 variant", "Sampling", "Severity of illness", "Socioeconomic Status", "Testing", "United States", "Variant", "Viral", "Virus", "Work", "World Health Organization", "base", "clinical care", "comorbidity", "coronavirus disease", "demographics", "diagnosis standard", "genome sequencing", "genomic data", "health care economics", "improved", "individual patient", "next generation sequencing", "pandemic disease", "pediatric patients", "sex", "social", "social determinants", "tertiary care", "transmission process", "sars-cov-2 sequencing", " genomics", " pediatrics" ], "approved": true } }, { "type": "Grant", "id": "5531", "attributes": { "award_id": "3P20GM103436-21S1", "title": "KY INBRE NOSI Supplement: Targeted COVID-19 Vaccine Decision Making Support for Sexual and Gender Minorities", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)" ], "program_reference_codes": [], "program_officials": [ { "id": 19218, "first_name": "Yang", "last_name": "Zhou", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2001-09-30", "end_date": "2024-04-30", "award_amount": 253183, "principal_investigator": { "id": 19219, "first_name": "MARTHA E", "last_name": "BICKFORD", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 795, "ror": "https://ror.org/01ckdn478", "name": "University of Louisville", "address": "", "city": "", "state": "KY", "zip": "", "country": "United States", "approved": true }, "abstract": "Since the World Health Organization declared COVID-19 a pandemic, 31.6 million Americans have contracted the SARS-CoV-2 virus and 566,000 have died. Effective and safe COVID-19 vaccines have been developed, tested, and deployed in record time and 219 million vaccine doses have been administered in the US. Racial and ethnic disparities in vaccine uptake have been noted, but data are not yet available for some other disadvantaged groups. Sexual and Gender Minorities (SGMs) are potentially at risk for vaccine hesitancy due to social and historical factors affecting vaccination in general and healthcare access specifically. There is a critical need to understand vaccine attitudes and behaviors among SGMs. Our long-term goal is to reduce potential health disparities in COVID-19 among SGMs. The overall objective is to develop and deploy a decision aid that supports SGM COVID-19 vaccine decision making. Using survey and focus group methods, and following accepted international standards for decision aid development, we will develop a tailored decision aid to reduce vaccine decisional conflict and improve vaccine acceptance. The project’s specific aims are to: 1. Generate foundational knowledge of COVID-19 vaccine hesitancy among SGMs. We hypothesize that SGMs overall will be somewhat less accepting of the vaccine than the general population and, among SGMs, there will be subgroups with other vaccine hesitancy risk factors (e.g., race, gender minority identity, political affiliation) who have significantly higher rates of vaccine hesitancy. 2. Produce contextualized understanding of intentions to receive the COVID-19 vaccine. We hypothesize the reasons for vaccine acceptance or hesitancy will differ among SGM subgroups. Focus group discussions with diverse samples of SGMs who are vaccine-hesitant will identify knowledge gaps, misconceptions, perceived barriers, negative attitudes such as stigma and mistrust, and preferences for decision support. The primary outcome will be determining decision support needs for SGM subgroups. 3. Create decision aids to reduce decision conflict and improve acceptance of the COVID-19 vaccine. We will generate a decision aid, or multiple versions of a decision aid, to empower the SGM decision maker to compare options for protection against COVID-19, clarify values, and support efficacy for gathering more information, collaborating with a healthcare partner in the decision-making process, and/or obtaining the COVID-19 vaccine. We hypothesize the tailored decision aids will reduce decision conflict and improve vaccine acceptance.", "keywords": [ "2019-nCoV", "Affect", "African American", "American", "Attitude", "Behavior", "Belief", "COVID-19", "COVID-19 vaccination", "COVID-19 vaccine", "Categories", "Cessation of life", "Conflict (Psychology)", "Contracts", "Data", "Decision Aid", "Decision Making", "Development", "Disadvantaged", "Dose", "Ethnic Origin", "Focus Groups", "Foundations", "General Population", "Goals", "Head", "Healthcare", "Herd Immunity", "Hispanics", "Income", "Individual", "Intention", "International", "Knowledge", "Latinx", "Measures", "Methods", "Motivation", "Natural Immunity", "Not Hispanic or Latino", "Outcome", "Pattern", "Politics", "Population", "Prevalence", "Process", "Race", "Recording of previous events", "Research", "Respiratory distress", "Risk", "Risk Factors", "Sampling", "Sex Differentiation", "Sexual and Gender Minorities", "Subgroup", "Surveys", "Testing", "Time", "United States", "Vaccinated", "Vaccination", "Vaccines", "Virus", "World Health Organization", "ethnic minority population", "gender minority", "health care availability", "health disparity", "improved", "intersectionality", "medically underserved", "medically underserved population", "pandemic disease", "preference", "primary outcome", "protective behavior", "psychosocial", "racial and ethnic disparities", "racial minority", "sexual minority", "shared decision making", "social", "social stigma", "stem", "tool", "underserved community", "vaccine acceptance", "vaccine hesitancy", "vaccine trial" ], "approved": true } }, { "type": "Grant", "id": "5540", "attributes": { "award_id": "3P20GM103408-21S1", "title": "Idaho INBRE SARS-CoV-2 variant surveillance using viral genome sequencing and analyses", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)" ], "program_reference_codes": [], "program_officials": [ { "id": 19242, "first_name": "KRISHAN", "last_name": "ARORA", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2001-09-30", "end_date": "2024-04-30", "award_amount": 737106, "principal_investigator": { "id": 19243, "first_name": "Carolyn Hovde", "last_name": "Bohach", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 984, "ror": "https://ror.org/03hbp5t65", "name": "University of Idaho", "address": "", "city": "", "state": "ID", "zip": "", "country": "United States", "approved": true }, "abstract": "(30-lines) This Idaho INBRE Program Administrative Supplement will fund a surveillance study of severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) in a unique study population. It will leverage the IDeA-built advanced-level bioinformatics infrastructure at the University of Idaho to sequence and analyze the genomes of SARS-CoV-2 circulating in the state. Idaho is primarily rural, poor, and geographically remote. The state ranks at or near the bottom among all states in the U.S. in health, education, socioeconomic status, and the number of primary-care physicians per capita. The study population will include the University of Idaho and the surrounding region. The University of Idaho has the only repository of SARS-CoV-2 clinical isolates in northern Idaho. Currently, there are 1,782 SARS-CoV-2 positive samples and based on projections, this number will increase to >2,400 over the next months; 2,100 viral genomes will be sequenced, assembled, and coupled with metadata to determine associations with specific times (travel/holidays), gender, and age groups. This data will be used in collaboration with the Idaho Department of Health & Welfare and the COBRE in Matrix in Biology to track the pandemic in rural communities. The entire northern Idaho region is critically missing from the state’s sequencing strategy as almost no commercial labs or hospitals testing for SARS-CoV-2 have saved positive samples. The proposal has three specific aims. Specific Aim 1 will sequence SARS-CoV-2 genomes from the unique Idaho study population and identify variants present over time. Specific Aim 2 will determine if SARS-CoV-2 variants are associated with outbreak events, specific times, and/or statewide travel by a highly mobile university student sub- population undergoing mandatory testing. Specific Aim 3 will determine how SARS-CoV-2 variants in the unique Idaho study population are distributed by gender and age groups. The mandatory university testing removes bias from a large subset of the positive samples and represents a unique opportunity to monitor the appearance and spread of new variants. Previous and ongoing positive viral isolates are or will be appropriately stored and cataloged. CDC/NIH-recommended protocols, standards, and resources for SARS-CoV-2 sequencing and data processing will be used. These analyses will contribute to our understanding of the dynamics of SARS-CoV-2 transmission, mutation, and the emergence of variants. SARS-CoV-2 variants are a major public health concern as they may increase infection rate, increase disease severity, and/or undermine immunization strategies. This work will advance and improve SARS- CoV-2 variant surveillance in Idaho.", "keywords": [ "2019-nCoV", "Administrative Supplement", "Age", "Appearance", "Bioinformatics", "Biology", "COVID testing", "COVID-19 testing", "Centers for Disease Control and Prevention (U.S.)", "Centers of Research Excellence", "Clinical", "Clinical Laboratory Improvement Amendments", "Collaborations", "Communicable Diseases", "Communities", "Core Facility", "Coupled", "Data", "Deposition", "Disease Outbreaks", "Environment", "Event", "Funding", "Genbank", "Gender", "Genome", "Genomics", "Geography", "Health", "Health Professional", "Health education", "Holidays", "Hospitals", "Idaho", "Immunization", "Influenza", "Institutional Review Boards", "Journals", "Laboratories", "Link", "Mandatory Testing", "Metadata", "Monitor", "Mutation", "Outcome", "Peer Review", "Policies", "Population", "Positioning Attribute", "Primary Care Physician", "Protocols documentation", "Public Health", "Publishing", "Research", "Research Design", "Research Personnel", "Resource Sharing", "Resources", "Rural", "Rural Community", "SARS-CoV-2 genome", "SARS-CoV-2 positive", "SARS-CoV-2 transmission", "SARS-CoV-2 variant", "Sampling", "Sequence Analysis", "Severity of illness", "Socioeconomic Status", "Testing", "Time", "Travel", "United States National Institutes of Health", "Universities", "Variant", "Viral", "Viral Genome", "Work", "age group", "base", "bioinformatics infrastructure", "computerized data processing", "data repository", "data sharing", "genome analysis", "genome sequencing", "improved", "infection rate", "pandemic disease", "programs", "repository", "rural underserved", "study population", "success", "surveillance study", "underserved area", "university student", "viral genomics", "welfare" ], "approved": true } }, { "type": "Grant", "id": "5603", "attributes": { "award_id": "3P20GM103429-20S1", "title": "Understanding Hesitant Adopters", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)" ], "program_reference_codes": [], "program_officials": [ { "id": 19408, "first_name": "KRISHAN", "last_name": "ARORA", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2001-09-30", "end_date": "2025-04-30", "award_amount": 253334, "principal_investigator": { "id": 19409, "first_name": "Lawrence E", "last_name": "Cornett", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 772, "ror": "", "name": "UNIV OF ARKANSAS FOR MED SCIS", "address": "", "city": "", "state": "AR", "zip": "", "country": "United States", "approved": true }, "abstract": "COVID-19 has become one of the leading causes of death in the United States (US), and racial and ethnic minority groups experience higher risks of exposure, hospitalization, and death due to COVID-19. Population immunity through the uptake of a vaccine is critical to stopping the spread of COVID-19; however, racial and ethnic disparities in vaccine hesitancy raise concerns about whether vaccination programs will further widen COVID-19 disparities. Minority populations have reported greater hesitancy to get the COVID-19 vaccine, with some communities of color half as likely to get the COVID-19 vaccine compared to Whites. To reduce disparities in COVID-19-related morbidity and mortality, we must understand and address racial disparities in vaccine behavior. The proposed study will utilize a mixed-methods nested-study approach including two steps of data collection. Data will be collected using random digit dialing to conduct a cell and landline phone survey of adult Arkansans (N=1800). Then, we will utilize a purposeful/random sample (N=50) drawn from the phone survey participants who are hesitant adopters (i.e., expressing both hesitancy and having received the COVID- 19 vaccination) for qualitative data collection. The purposeful sample for the qualitative portion will provide rich qualitative data on hesitant adopters. Both sampling methods will oversample Black/African American and Hispanic/Latino participants. Our specific aims are: Aim 1. Examine characteristics associated with vaccine hesitancy/willingness and vaccine behavior (e.g., vaccinated or not) between and within racial/ethnic groups using quantitative methods (random sample of N=1800) informed by the Increasing Vaccination Model. Aim 2. Examine the characteristics that distinguish hesitant adopters from hesitant non-adopters using quantitative methods (random sample of N=1800) informed by the Increasing Vaccination Model. Aim 3. Examine the role of thoughts and feelings, social processes, motivations and practical issues in the process of becoming compliant among those who are hesitant and get vaccinated using qualitative methods (purposeful random sample N= 50) in a nested design informed by the Increasing Vaccination Model. Although there is much research documenting the problem of vaccine hesitancy and differences in hesitancy based on race and ethnicity, almost no studies provide information about what might be done about it. Examining those who are hesitant but are vaccinated is key to better understanding factors which might increase uptake despite hesitancy. This study will provide new and actionable information that researchers and healthcare providers can use to create interventions to increase vaccination uptake among the hesitant.", "keywords": [ "Address", "Adult", "Affect", "African American", "Arkansas", "Award", "Behavior", "COVID-19", "COVID-19 disparity", "COVID-19 morbidity", "COVID-19 mortality", "COVID-19 vaccination", "COVID-19 vaccine", "Cause of Death", "Cells", "Characteristics", "Color", "Communities", "Consent Forms", "Data", "Data Collection", "Death Rate", "Development", "Digit structure", "Ethnic Origin", "Ethnic group", "Feedback", "Feeling", "Health Personnel", "Hispanics", "Hospitalization", "Immunity", "Immunization Programs", "Individual", "Institutional Review Boards", "Intervention", "Interview", "Knowledge", "Latino", "Literature", "Methods", "Minority Groups", "Modeling", "Motivation", "Not Hispanic or Latino", "Participant", "Pattern", "Population", "Process", "Protocols documentation", "Qualitative Methods", "Race", "Recommendation", "Reporting", "Research", "Research Design", "Research Personnel", "Role", "Sampling", "Social Processes", "Source", "Surveys", "Telephone", "Thinking", "Time", "Trust", "United States", "Vaccinated", "Vaccination", "Vaccines", "Variant", "base", "community based participatory research", "design", "disparity reduction", "ethnic minority population", "experience", "health disparity", "high risk", "hospitalization rates", "infection rate", "innovation", "member", "mortality", "pandemic disease", "public health relevance", "racial and ethnic", "racial and ethnic disparities", "racial disparity", "racial minority", "uptake", "vaccine acceptance", "vaccine hesitancy", "willingness" ], "approved": true } }, { "type": "Grant", "id": "5894", "attributes": { "award_id": "3P20GM103451-21S1", "title": "Deep sequencing SARS-CoV-2 samples from New Mexico to interrogate immunological selection on genetic variants", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)" ], "program_reference_codes": [], "program_officials": [ { "id": 20164, "first_name": "LAKSHMI KUMAR", "last_name": "Matukumalli", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2001-09-30", "end_date": "2024-03-31", "award_amount": 734660, "principal_investigator": { "id": 20165, "first_name": "SHELLEY", "last_name": "LUSETTI", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1173, "ror": "", "name": "NEW MEXICO STATE UNIVERSITY LAS CRUCES", "address": "", "city": "", "state": "NM", "zip": "", "country": "United States", "approved": true }, "abstract": "Although vaccination has blunted the impact of the SARS-CoV-2 pandemic in several countries, the future impact of this virus will depend on its transmissibility, virulence, and ability to evade naturally-acquired and vaccine- mediated immunity. All three phenotypes are currently in flux due to the evolution and spread of novel SARS- CoV-2 variants of concern. Importantly, all of these variants rose to prominence prior to widespread vaccination. Thus, while some may be the product of immune-mediated selection, they did not evolve in response to vaccination per se, and we know next to nothing about whether and how vaccination imposes selection on SARS-CoV-2. To close this knowledge gap, the proposed research will address the question: Do vaccinated study participants still acquire the SARS-CoV-2 virus, and if so, what variants do they carry? We hypothesize that vaccine-mediated immunity may impose selection on variants in one of three ways: (i) between- host selection in which vaccinees are more likely to be infected by variants pre-adapted for immune escape, (ii) within-host selection in which novel variants with capacity for immune escape first evolve in individual vaccinees, and may then be transmitted to vaccinated or unvaccinated individuals, or (iii) a combination of within- and between host selection. Furthermore, we hypothesize that vaccine-mediated immunity will impose stronger selection on SARS-CoV-2 than naturally-induced immunity or mAb therapy. Inferring patterns of within-host selection requires data on within-host population variation, but to date, studies of within-host populations of SARS-CoV-2 have been largely neglected in favor of consensus sequences. Thus, we will obtain residual material from SARS-CoV-2 positive samples from the following groups: (1) ≥ 100 individuals infected at least 5 days and any interval thereafter following vaccination, (2) ≥50 individuals being treated with mAbs, (3) 200 to 400 persistently infected individuals testing positive at least 5 days following an initial positive test, and (4) the first positive test from 100 individuals testing positive early in the pandemic, to represent a control group that is likely at an early point in their first infection. These samples will be provided by Tricore labs from individuals tested in New Mexico. RNA extracted from samples will be subject to both Illumina and PacBio sequencing; data from both approaches will be used to detect consensus variants, indels, and intra-host single-nucleotide variants (iSNVs) at frequencies >2%, and the longer-read Pac Bio data will be used to assess linkage between mutations, facilitating detection of recombination, e.g. (20), and mixed-variant infections (co-infection). These data will be used to quantify intra-host diversity and selection, frequency of common, sub-consensus mutations, convergent evolution of high-risk mutations present in VOC. Phylogenetic association of iSNVs will also be analyzed. Novel mutations that fall within documented antibody binding sites or T cell epitopes will be flagged and scrutinized for spread.", "keywords": [ "2019-nCoV", "Address", "Antibody Binding Sites", "COVID-19 pandemic", "COVID-19 vaccine", "Centers for Disease Control and Prevention (U.S.)", "Cities", "Codon Nucleotides", "Consensus", "Consensus Sequence", "Control Groups", "Country", "Data", "Detection", "Evolution", "Frequencies", "Funding", "Future", "Genes", "Genetic Recombination", "Genome", "Geography", "Immune", "Immune Evasion", "Immune response", "Immunity", "Immunologics", "Individual", "Infection", "Knowledge", "Light", "Mediating", "Monoclonal Antibodies", "Monoclonal Antibody Therapy", "Mutation", "New Mexico", "Nucleotides", "Participant", "Pattern", "Phenotype", "Phylogenetic Analysis", "Population", "RNA", "Research", "Residual state", "SARS-CoV-2 B.1.351", "SARS-CoV-2 immunity", "SARS-CoV-2 positive", "SARS-CoV-2 variant", "Sampling", "Single Nucleotide Polymorphism", "Statistical Data Interpretation", "T-Lymphocyte Epitopes", "Testing", "Vaccinated", "Vaccination", "Vaccines", "Variant", "Viral", "Viral Genome", "Virulence", "Virus", "base", "co-infection", "deep sequencing", "experimental study", "falls", "flexibility", "genetic variant", "high risk", "human coronavirus", "insertion/deletion mutation", "neglect", "novel", "pandemic disease", "response", "stem", "success", "vaccine hesitancy", "vaccine-induced immunity", "variants of concern" ], "approved": true } } ], "meta": { "pagination": { "page": 1384, "pages": 1405, "count": 14046 } } }